Posted by Michael Wonder on 26 Feb 2016
Lilly receives positive CHMP opinion for ixekizumab for the treatment of moderate-to-severe plaque psoriasis
26 February 2016 - Ixekizumab is designed to specifically target IL-17A, a protein that plays a key role in driving underlying inflammation in psoriasis.
For more details, go to: https://investor.lilly.com/releasedetail.cfm?ReleaseID=957455
